Boston Scientific's stock fell 9.03% following clinical trial updates on its Watchman implant. Despite meeting safety and efficacy goals, investor reactions were tepid.
May 15, 2026
May 15, 2026
May 15, 2026
May 15, 2026
May 15, 2026
May 15, 2026
May 15, 2026
May 15, 2026